Literature DB >> 22605504

Tumor response assessment by modified Choi criteria in localized high-risk soft tissue sarcoma treated with chemotherapy.

Silvia Stacchiotti1, Paolo Verderio, Antonella Messina, Carlo Morosi, Paola Collini, Antonio Llombart-Bosch, Javier Martin, Alessandro Comandone, Jurado Cruz, Andrea Ferraro, Giovanni Grignani, Sara Pizzamiglio, Vittorio Quagliuolo, Piero Picci, Sergio Frustaci, Angelo Paolo Dei Tos, Paolo G Casali, Alessandro Gronchi.   

Abstract

BACKGROUND: The objective of this study was to compare the prognostic relevance of Response Evaluation Criteria in Solid Tumors (RECIST) versus Choi criteria for the assessment of response in patients with high-risk soft tissue sarcoma of the extremities or trunk wall who received preoperative chemotherapy with or without radiotherapy in a phase 3 trial.
METHODS: Patients received 3 cycles of preoperative epirubicin + ifosfamide with or without radiotherapy. The diagnostic concordance between RECIST and Choi criteria and their correlation with overall survival (OS) and freedom from progression (FFP) were evaluated in a univariate Cox regression model.
RESULTS: In 243 of 321 eligible patients, RECIST, Choi criteria, and histology were predictive for OS and FFP. In the subgroup of 69 patients who received chemotherapy alone and were evaluable by both RECIST and Choi criteria, Choi criteria were associated significantly with OS and FFP, whereas RECIST predicted only FFP, and the pattern of agreement observed between the 2 criteria was unsatisfactory. On a dichotomous scale, comparing objective response (complete and partial responses) and lack of response (stable and progressive disease) to preoperative chemotherapy according to RECIST and Choi criteria, only Choi criteria were predictive of OS and FFP, and fair agreement between RECIST and Choi criteria was observed. When lack of progression and progression were compared (complete and partial responses + stable disease vs progressive disease), both assessment criteria were significantly predictive of OS and FFP, and there was substantial agreement between the 2 criteria.
CONCLUSIONS: Response to chemotherapy with or without radiotherapy was associated with a better outcome in patients with high-risk soft tissue sarcoma. Choi criteria were better predictors than RECIST in patients who received preoperative chemotherapy alone.
Copyright © 2012 American Cancer Society.

Entities:  

Mesh:

Year:  2012        PMID: 22605504     DOI: 10.1002/cncr.27624

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  20 in total

1.  mTOR-inhibitor treatment of metastatic renal cell carcinoma: contribution of Choi and modified Choi criteria assessed in 2D or 3D to evaluate tumor response.

Authors:  M Lamuraglia; S Raslan; R Elaidi; S Oudard; B Escudier; K Slimane; R Renard Penna; M Wagner; O Lucidarme
Journal:  Eur Radiol       Date:  2015-05-08       Impact factor: 5.315

2.  Neoadjuvant radiation in primary extremity liposarcoma: correlation of MRI features with histopathology.

Authors:  Jeremy R Wortman; Sree Harsha Tirumani; Harika Tirumani; Atul B Shinagare; Jyothi P Jagannathan; Jason L Hornick; Nikhil H Ramaiya
Journal:  Eur Radiol       Date:  2015-08-28       Impact factor: 5.315

Review 3.  Preoperative therapy for extremity soft tissue sarcomas.

Authors:  Lara E Davis; Christopher W Ryan
Journal:  Curr Treat Options Oncol       Date:  2015-06

Review 4.  Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer.

Authors:  Robert Michael Kwee; Thomas Christian Kwee
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

Review 5.  Virtual Biopsy in Soft Tissue Sarcoma. How Close Are We?

Authors:  Amani Arthur; Edward W Johnston; Jessica M Winfield; Matthew D Blackledge; Robin L Jones; Paul H Huang; Christina Messiou
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

6.  High-grade soft-tissue sarcoma: optimizing injection improves MRI evaluation of tumor response.

Authors:  Amandine Crombé; François Le Loarer; François Cornelis; Eberhardt Stoeckle; Xavier Buy; Sophie Cousin; Antoine Italiano; Michèle Kind
Journal:  Eur Radiol       Date:  2018-07-23       Impact factor: 5.315

7.  Prognostic significance of treatment-induced pathologic necrosis in extremity and truncal soft tissue sarcoma after neoadjuvant chemoradiotherapy.

Authors:  John T Mullen; Francis J Hornicek; David C Harmon; Kevin A Raskin; Yen-Lin Chen; Jackie Szymonifka; Beow Y Yeap; Edwin Choy; Thomas F DeLaney; G Petur Nielsen
Journal:  Cancer       Date:  2014-07-31       Impact factor: 6.860

8.  A randomised phase II trial of selumetinib vs selumetinib plus temsirolimus for soft-tissue sarcomas.

Authors:  Z Eroglu; H A Tawbi; J Hu; M Guan; P H Frankel; N H Ruel; S Wilczynski; S Christensen; D R Gandara; W A Chow
Journal:  Br J Cancer       Date:  2015-04-21       Impact factor: 7.640

9.  Trabectedin in the neoadjuvant treatment of high-grade pleomorphic sarcoma: report of a rare case and literature review.

Authors:  Markus K Schuler; Stephan Richter; Ivan Platzek; Bettina Beuthien-Baumann; Kathrin Wieczorek; Christine Hamann; Johannes Mohm; Gerhard Ehninger
Journal:  Case Rep Oncol Med       Date:  2013-01-16

10.  Response to trabectedin in a patient with advanced synovial sarcoma with lung metastases.

Authors:  Elisa Zanardi; Marco Maruzzo; Maria C Montesco; Anna Roma; Marco Rastrelli; Umberto Basso
Journal:  Anticancer Drugs       Date:  2014-11       Impact factor: 2.248

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.